Literature DB >> 3505770

Circulating 1 alpha,25-dihydroxyvitamin D levels after a single dose of 1 alpha,25-dihydroxyvitamin D3 or 1 alpha-hydroxyvitamin D3 in normal men.

Y Seino1, H Tanaka, K Yamaoka, H Yabuuchi.   

Abstract

In order to clarify the differences between 1 alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) and 1 alpha-hydroxyvitamin D3 (1(OH)D3) as a drug, we determined the serum levels of 1,25(OH)2D at different times after oral administration of each drug to normal men. In the paired test which was carried out on the same people, the integrated change of serum 1,25(OH)2D levels, defined as the mean area under the concentration curve over 24 h, was significantly higher in the 1,25(OH)2D3 group than in the 1(OH)D3 group. The mean of the peak serum level (Cmax) was also significantly higher in the former group. On the other hand, the mean time to reach the peak level (Tmax) was significantly shorter in the 1,25(OH)2D3 group than in the 1(OH)D3 group. The same results were obtained even when we performed the non-paired administration tests. In the present study, the peak serum level of 1,25(OH)2D after ingestion of a single dose of 1,25(OH)2D3 was reached rapidly, i.e., between 4 and 6 h, and the value had usually returned to the baseline by 24 h. On the contrary, 1(OH)D3 administration resulted in a slow rise in the serum level of 1,25(OH)2D with a relatively low peak level. Therefore, clinical use of these two drugs demands careful consideration of their differences.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3505770

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  7 in total

Review 1.  Vitamin D resistance and colon cancer prevention.

Authors:  Charles Giardina; James P Madigan; Cassandra A Godman Tierney; Bruce M Brenner; Daniel W Rosenberg
Journal:  Carcinogenesis       Date:  2011-12-16       Impact factor: 4.944

2.  The development of vitamin D3 analogues for the treatment of osteoporosis.

Authors:  Y Nishii; K Sato; T Kobayashi
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

3.  In vivo evidence for a novel pathway of vitamin D₃ metabolism initiated by P450scc and modified by CYP27B1.

Authors:  Andrzej T Slominski; Tae-Kang Kim; Haleem Z Shehabi; Igor Semak; Edith K Y Tang; Minh N Nguyen; Heather A E Benson; Elena Korik; Zorica Janjetovic; Jianjun Chen; Charles R Yates; Arnold Postlethwaite; Wei Li; Robert C Tuckey
Journal:  FASEB J       Date:  2012-06-08       Impact factor: 5.191

Review 4.  Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol.

Authors:  Johann D Ringe; Erich Schacht
Journal:  Rheumatol Int       Date:  2004-06-30       Impact factor: 2.631

5.  Transformation of vitamin D3 to 1 alpha,25-dihydroxyvitamin D3 via 25-hydroxyvitamin D3 using Amycolata sp. strains.

Authors:  J Sasaki; A Miyazaki; M Saito; T Adachi; K Mizoue; K Hanada; S Omura
Journal:  Appl Microbiol Biotechnol       Date:  1992-11       Impact factor: 4.813

6.  Transformation of 25- and 1 alpha-hydroxyvitamin D3 to 1 alpha, 25-dihydroxyvitamin D3 by using Streptomyces sp. strains.

Authors:  J Sasaki; A Mikami; K Mizoue; S Omura
Journal:  Appl Environ Microbiol       Date:  1991-10       Impact factor: 4.792

7.  Metabolism of 1alpha-hydroxyvitamin D3 by cytochrome P450scc to biologically active 1alpha,20-dihydroxyvitamin D3.

Authors:  Robert C Tuckey; Zorica Janjetovic; Wei Li; Minh N Nguyen; Michal A Zmijewski; Jordan Zjawiony; Andrzej Slominski
Journal:  J Steroid Biochem Mol Biol       Date:  2008-10-21       Impact factor: 4.292

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.